Press release content from Globe Newswire. The AP news staff was not involved in its creation. Remestemcel-L Reduces Mortality in Patients Less Than 65 Years Old With Moderate/Severe ... Mesoblast LimitedApril 29, 2021 GMT Remestemcel-L reduced mortality through 60 days in the pre-specified population under 65 years old In these patients the benefit was further increased when remestemcel-L was used with dexamethasone as part of standard of care Mortality reduction by remestemcel-L was accompanied by increased days alive off mechanical ventilation and reduced days in hospital Plan to meet with U.S. Food and Drug Administration (FDA) to discuss potential next steps NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the 60 day results from the randomized controlled trial of remestemcel-L in 222 ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) which had been halted after the third interim analysis, as previously announced. Remestemcel-L reduced mortality through day 60 by 46% in the pre-specified group below age 65, but not in patients 65 or older. Remestemcel-L reduced mortality by 75% and increased days alive off mechanical ventilation in patients under age 65 when combined with dexamethasone, in comparison with controls on dexamethasone.